G1 Therapeutics (NASDAQ:GTHX) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of G1 Therapeutics (NASDAQ:GTHXGet Rating) from a sell rating to a hold rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “

Separately, Needham & Company LLC reiterated a buy rating and set a $44.00 target price on shares of G1 Therapeutics in a research note on Thursday, April 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, G1 Therapeutics presently has a consensus rating of Buy and a consensus target price of $37.00.

Shares of G1 Therapeutics stock opened at $4.61 on Tuesday. The firm has a fifty day simple moving average of $7.24 and a 200-day simple moving average of $9.88. The company has a current ratio of 5.96, a quick ratio of 5.73 and a debt-to-equity ratio of 0.76. G1 Therapeutics has a 1-year low of $4.32 and a 1-year high of $24.12. The stock has a market capitalization of $196.87 million, a price-to-earnings ratio of -1.14 and a beta of 2.03.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last released its earnings results on Wednesday, May 4th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.17). G1 Therapeutics had a negative net margin of 708.20% and a negative return on equity of 107.75%. During the same quarter last year, the firm earned ($0.65) EPS. As a group, research analysts predict that G1 Therapeutics will post -3.86 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in GTHX. Wells Fargo & Company MN increased its holdings in G1 Therapeutics by 23.0% in the 2nd quarter. Wells Fargo & Company MN now owns 96,799 shares of the company’s stock valued at $2,124,000 after buying an additional 18,102 shares during the period. Morgan Stanley increased its holdings in G1 Therapeutics by 142.0% in the 2nd quarter. Morgan Stanley now owns 572,061 shares of the company’s stock valued at $12,551,000 after buying an additional 335,635 shares during the period. SG Americas Securities LLC increased its holdings in G1 Therapeutics by 47.7% in the 3rd quarter. SG Americas Securities LLC now owns 59,576 shares of the company’s stock valued at $800,000 after buying an additional 19,229 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in G1 Therapeutics by 29.1% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 16,917 shares of the company’s stock valued at $227,000 after buying an additional 3,812 shares during the period. Finally, Raymond James & Associates increased its holdings in G1 Therapeutics by 1.6% in the 3rd quarter. Raymond James & Associates now owns 134,739 shares of the company’s stock valued at $1,808,000 after buying an additional 2,091 shares during the period. 61.89% of the stock is currently owned by hedge funds and other institutional investors.

About G1 Therapeutics (Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Further Reading

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.